Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis

Abstract

Several studies have explored the use of NOACs compared with vitamin K antagonists (VKAs) in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF); and therefore, we aimed to compare the efficacy and safety outcomes of NOACs with VKAs in this population. We systematically searched the PubMed and Embase databases until August 5, 2019 for studies that compared the effect of NOACs with VKAs in patients with HCM and AF. The risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. A total of four observational studies were included in this meta-analysis. Overall, compared with VKAs use, the use of NOACs was associated with reduced risks of ischemic stroke (RR 0.49, 95% CI 0.34–0.69), all-cause death (RR 0.44, 95% CI 0.35–0.55), and intracranial hemorrhage (RR 0.43, 95% CI 0.24–0.77). There were no differences in the risks of stroke or systemic embolism, major or clinically relevant bleeding, and gastrointestinal bleeding in patients with NOACs versus VKAs. Re-analyses with a fixed-effects model produced the similar results as the main analyses. For the efficacy and safety outcomes, comparisons of NOACs versus warfarin produced the similar results as those of NOACs versus VKAs. Based on current data from observational studies, compared with VKAs, NOACs had similar or lower risks of thromboembolic and bleeding events in patients with HCM and AF.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH (2017) Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res 120(9):1501–1517

    CAS  Article  Google Scholar 

  2. 2.

    Guttmann OP, Rahman MS, O’Mahony C, Anastasakis A, Elliott PM (2014) Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 100(6):465–472

    Article  Google Scholar 

  3. 3.

    Vaidya K, Semsarian C, Chan KH (2017) Atrial fibrillation in hypertrophic cardiomyopathy. Heart Lung Circ 26(9):975–982

    Article  Google Scholar 

  4. 4.

    Borer J, Atar D, Marciniak T, Kim M, Serebruany V (2019) Atrial fibrillation and stroke in patients with hypertrophic cardiomyopathy: important new insights. Thromb Haemosts 119(3):355–357

    Article  Google Scholar 

  5. 5.

    Jung H, Yang P, Sung J, Jang E, Yu H, Kim T, Uhm J, Kim J, Pak H, Lee M, Lip G, Joung B (2019) Hypertrophic cardiomyopathy in patients with atrial fibrillation: prevalence and associated stroke risks in a nationwide cohort study. Thromb Haemost 119(02):285–293

    Article  Google Scholar 

  6. 6.

    Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35(39):2733–2779

    Article  Google Scholar 

  7. 7.

    Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, Casey SA, Gohman TE, Bongioanni S, Spirito P (2002) Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 39(2):301–307

    Article  Google Scholar 

  8. 8.

    Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM (2013) Edoxaban versus warfarin in patients with atrial fibrillation. New Engl J Med 369(22):2093–2104

    CAS  Article  Google Scholar 

  9. 9.

    Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 365(11):981–992

    CAS  Article  Google Scholar 

  10. 10.

    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 365(10):883–891

    CAS  Article  Google Scholar 

  11. 11.

    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H, Joyner CD, Wallentin L (2009) Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 361(12):1139–1151

    CAS  Article  Google Scholar 

  12. 12.

    Jung H, Yang P, Jang E, Yu HT, Kim T, Uhm J, Kim J, Pak H, Lee M, Joung B, Lip GYH (2019) Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy. Chest 155(2):354–363

    Article  Google Scholar 

  13. 13.

    Dominguez F, Climent V, Zorio E, Ripoll-Vera T, Salazar-Mendiguchía J, García-Pinilla JM, Urbano-Moral JA, Fernández-Fernández X, Lopez-Cuenca D, Ajo-Ferrer R, Sanz-Sanchez J, Gomez-Perez Y, López-Garrido MA, Barriales-Villa R, Gimeno JR, Garcia-Pavia P (2017) Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. Int J Cardiol 248:232–238

    Article  Google Scholar 

  14. 14.

    Noseworthy PA, Yao X, Shah ND, Gersh BJ (2016) Stroke and bleeding risks in NOAC- and warfarin-treated patients with hypertrophic cardiomyopathy and atrial fibrillation. J Am Coll Cardiol 67(25):3020–3021

    Article  Google Scholar 

  15. 15.

    Lee H, Kim H, Jung J, Han K, Lee H, Park J, Kim HM, Kim Y, Ommen SR (2019) Novel oral anticoagulants for primary stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation. Stroke 50(9):2582–2586

    CAS  Article  Google Scholar 

  16. 16.

    Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0[updated March 2011]. www.cochrane-handbook.org. Accessed Aug 10, 2019

  17. 17.

    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097

    Article  Google Scholar 

  18. 18.

    Wells GA, Shea B, O Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2014. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed Aug 10 2019

  19. 19.

    Zhu W, Guo L, Hong K (2016) Relationship between smoking and adverse outcomes in patients with atrial fibrillation: a meta-analysis and systematic review. Int J Cardiol 222:289–294

    Article  Google Scholar 

  20. 20.

    Verdecchia P, Reboldi G, Angeli F, Mazzotta G, Lip G, Brueckmann M, Kleine E, Wallentin L, Ezekowitz MD, Yusuf S, Connolly SJ, Di Pasquale G (2018) Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. Europace 20(2):253–262

    Article  Google Scholar 

  21. 21.

    January CT, Wann LS, Calkins H, Field ME, Chen LY, Furie KL, Cigarroa JE, Heidenreich PA, Cleveland JJ, Murray KT, Ellinor PT, Shea JB, Ezekowitz MD, Tracy CM, Yancy CW (2019) 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 16(8):e66–e93

    Article  Google Scholar 

  22. 22.

    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GYH, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 18(11):1609–1678

    Article  Google Scholar 

  23. 23.

    January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JJ, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64(21):e1–e76

    Article  Google Scholar 

  24. 24.

    JCS Joint Working Group (2014) Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circ J 78(8):1997–2021

    Article  Google Scholar 

  25. 25.

    Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: A report of the American College of cardiology foundation/American heart association task force on practice guidelines. Circulation 124(24):2761–2796

    Article  Google Scholar 

  26. 26.

    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GYH, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893–2962

    Article  Google Scholar 

Download references

Funding

None.

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Yunguo Zhou or Wengen Zhu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 1131 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhou, Y., He, W., Zhou, Y. et al. Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis. J Thromb Thrombolysis 50, 311–317 (2020). https://doi.org/10.1007/s11239-019-02008-3

Download citation

Keywords

  • Atrial fibrillation
  • Hypertrophic cardiomyopathy
  • Anticoagulants
  • Efficacy
  • Safety